BeOne Medicines Ltd. — Director's Dealing 2019

May 2, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2019-05-01

Reporting Person: OYLER JOHN (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-05-01	American Depositary Shares	S	1402	$124.7861	Disposed	1422	Direct
2019-05-01	American Depositary Shares	S	1371	$125.5294	Disposed	51	Direct
2019-05-01	American Depositary Shares	S	51	$126.5412	Disposed	0	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	17261533	Direct
Ordinary Shares	7743227	Indirect
Ordinary Shares	29439115	Indirect
Ordinary Shares	10000000	Indirect
Ordinary Shares	102188	Indirect

Footnotes

F1: These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.

F2: These securities are held by Oyler Investment LLC, of which 99% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.

F3: These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account.

F4: These securities are held by The John Oyler Legacy Trust, of which the Reporting Person's father is a trustee, for the benefit of the Reporting Person's minor child, for which the Reporting Person disclaims beneficial ownership.

F5: Each American Depositary Share represents 13 Ordinary Shares

F6: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover tax withholdings in connection with the vesting of a restricted share unit award previously granted to the Reporting Person.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.19 to $125.04, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.25 to $126.21, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.44 to $126.56, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price.